Conversation on Medicare: Outlook For Part B Drug Reimbursement
This article was originally published in The Pink Sheet Daily
Arnold & Porter attorneys Grant Bagley and Rosemary Maxwell discuss the impact of CMS’ policies on coverage with evidence development and the competitive acquisition program.
You may also be interested in...
The US FDA has added hydroxychloroquine sulfate to the list of drugs outsourcing facilities can compound as pharmacy group calls for more such approvals with COVID-19 driving demand for additional prescription and over-the-counter drugs.
AstraZeneca emptied its warehouses in January. “We said, OK let us pack everything and get it out in the door,” said Tony Mire-Sluis, head of global quality. The firm is allowing only crucial personnel in plants, or those responsible for running a plant or moving products; all others are working from home.
Quality experts with AstraZeneca and Thermo Fisher describe how their companies are responding to the COVID-19 pandemic – but urge industry not to lose focus on monitoring unrelated drug products.